APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

AT1 Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global AT1 Receptor Antagonists Market Outlook and Growth Opportunities 2026

Report ID 173967860421 December 2025198 pages

Choose your research edition.

Industry ResearchAT1 Receptor Antagonists Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal AT1 Receptor Antagonists Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal AT1 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AT1 Receptor Antagonists Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal AT1 Receptor Antagonists Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global AT1 Receptor Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for AT1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for AT1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AT1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the AT1 Receptor Antagonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the AT1 Receptor Antagonists market include Teva Pharmaceutical, Sanofi, Jhonson and Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global AT1 Receptor Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of AT1 Receptor Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents AT1 Receptor Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the AT1 Receptor Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

AT1 Receptor Antagonists Segment by Company

Teva Pharmaceutical

Sanofi

Jhonson and Johnson

Novartis

Merck

Eli Lilly

Pfizer

GSK

Bayer

Bristol-Myers Squibb

Astra Zeneca

AT1 Receptor Antagonists Segment by Type

Valsartan

Telmisartan

Losartan

Irbesartan

Olmesartan

Azilsartan

AT1 Receptor Antagonists Segment by Application

Cardiovascular Diseases

Kidney Diseases

Hypertension

Other

AT1 Receptor Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global AT1 Receptor Antagonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions AT1 Receptor Antagonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify AT1 Receptor Antagonists significant trends, drivers, influence factors in global and regions.

6. To analyze AT1 Receptor Antagonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AT1 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AT1 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AT1 Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the AT1 Receptor Antagonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AT1 Receptor Antagonists industry.

Chapter 3: Detailed analysis of AT1 Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of AT1 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of AT1 Receptor Antagonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. AT1 Receptor Antagonists Industry Trends Table 2. AT1 Receptor Antagonists Industry Drivers Table 3. AT1 Receptor Antagonists Industry Opportunities and Challenges Table 4. AT1 Receptor Antagonists Industry Restraints Table 5. Global AT1 Receptor Antagonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global AT1 Receptor Antagonists Revenue Share by Company (2021-2026) Table 7. Global AT1 Receptor Antagonists Sales Volume by Company (k tons) & (2021-2026) Table 8. Global AT1 Receptor Antagonists Sales Volume Share by Company (2021-2026) Table 9. Global AT1 Receptor Antagonists Average Price (US$/ton) of Company (2021-2026) Table 10. Global AT1 Receptor Antagonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global AT1 Receptor Antagonists Key Company Manufacturing Base & Headquarters Table 12. Global AT1 Receptor Antagonists Company, Product Type & Application Table 13. Global AT1 Receptor Antagonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global AT1 Receptor Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Valsartan Table 18. Significant Companies of Telmisartan Table 19. Significant Companies of Losartan Table 20. Significant Companies of Irbesartan Table 21. Significant Companies of Olmesartan Table 22. Significant Companies of Azilsartan Table 23. Global AT1 Receptor Antagonists Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 24. Global AT1 Receptor Antagonists Sales Volume by Type (2021-2026) & (k tons) Table 25. Global AT1 Receptor Antagonists Sales Volume by Type (2027-2032) & (k tons) Table 26. Global AT1 Receptor Antagonists Sales Volume Share by Type (2021-2026) Table 27. Global AT1 Receptor Antagonists Sales Volume Share by Type (2027-2032) Table 28. Global AT1 Receptor Antagonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global AT1 Receptor Antagonists Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global AT1 Receptor Antagonists Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global AT1 Receptor Antagonists Sales Value Share by Type (2021-2026) Table 32. Global AT1 Receptor Antagonists Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Cardiovascular Diseases Table 34. Significant Companies of Kidney Diseases Table 35. Significant Companies of Hypertension Table 36. Significant Companies of Other Table 37. Global AT1 Receptor Antagonists Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 38. Global AT1 Receptor Antagonists Sales Volume by Application (2021-2026) & (k tons) Table 39. Global AT1 Receptor Antagonists Sales Volume by Application (2027-2032) & (k tons) Table 40. Global AT1 Receptor Antagonists Sales Volume Share by Application (2021-2026) Table 41. Global AT1 Receptor Antagonists Sales Volume Share by Application (2027-2032) Table 42. Global AT1 Receptor Antagonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global AT1 Receptor Antagonists Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global AT1 Receptor Antagonists Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global AT1 Receptor Antagonists Sales Value Share by Application (2021-2026) Table 46. Global AT1 Receptor Antagonists Sales Value Share by Application (2027-2032) Table 47. Global AT1 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 48. Global AT1 Receptor Antagonists Sales by Region (2021-2026) & (k tons) Table 49. Global AT1 Receptor Antagonists Sales Market Share by Region (2021-2026) Table 50. Global AT1 Receptor Antagonists Sales by Region (2027-2032) & (k tons) Table 51. Global AT1 Receptor Antagonists Sales Market Share by Region (2027-2032) Table 52. Global AT1 Receptor Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global AT1 Receptor Antagonists Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global AT1 Receptor Antagonists Sales Value Share by Region (2021-2026) Table 55. Global AT1 Receptor Antagonists Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global AT1 Receptor Antagonists Sales Value Share by Region (2027-2032) Table 57. Global AT1 Receptor Antagonists Market Average Price (US$/ton) by Region (2021-2026) Table 58. Global AT1 Receptor Antagonists Market Average Price (US$/ton) by Region (2027-2032) Table 59. Global AT1 Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 60. Global AT1 Receptor Antagonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global AT1 Receptor Antagonists Sales by Country (2021-2026) & (k tons) Table 62. Global AT1 Receptor Antagonists Sales Market Share by Country (2021-2026) Table 63. Global AT1 Receptor Antagonists Sales by Country (2027-2032) & (k tons) Table 64. Global AT1 Receptor Antagonists Sales Market Share by Country (2027-2032) Table 65. Global AT1 Receptor Antagonists Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global AT1 Receptor Antagonists Sales Value Market Share by Country (2021-2026) Table 67. Global AT1 Receptor Antagonists Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global AT1 Receptor Antagonists Sales Value Market Share by Country (2027-2032) Table 69. Teva Pharmaceutical Company Information Table 70. Teva Pharmaceutical Business Overview Table 71. Teva Pharmaceutical AT1 Receptor Antagonists Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 72. Teva Pharmaceutical AT1 Receptor Antagonists Product Portfolio Table 73. Teva Pharmaceutical Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi AT1 Receptor Antagonists Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 77. Sanofi AT1 Receptor Antagonists Product Portfolio Table 78. Sanofi Recent Development Table 79. Jhonson and Johnson Company Information Table 80. Jhonson and Johnson Business Overview Table 81. Jhonson and Johnson AT1 Receptor Antagonists Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 82. Jhonson and Johnson AT1 Receptor Antagonists Product Portfolio Table 83. Jhonson and Johnson Recent Development Table 84. Novartis Company Information Table 85. Novartis Business Overview Table 86. Novartis AT1 Receptor Antagonists Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 87. Novartis AT1 Receptor Antagonists Product Portfolio Table 88. Novartis Recent Development Table 89. Merck Company Information Table 90. Merck Business Overview Table 91. Merck AT1 Receptor Antagonists Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 92. Merck AT1 Receptor Antagonists Product Portfolio Table 93. Merck Recent Development Table 94. Eli Lilly Company Information Table 95. Eli Lilly Business Overview Table 96. Eli Lilly AT1 Receptor Antagonists Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 97. Eli Lilly AT1 Receptor Antagonists Product Portfolio Table 98. Eli Lilly Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer AT1 Receptor Antagonists Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 102. Pfizer AT1 Receptor Antagonists Product Portfolio Table 103. Pfizer Recent Development Table 104. GSK Company Information Table 105. GSK Business Overview Table 106. GSK AT1 Receptor Antagonists Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 107. GSK AT1 Receptor Antagonists Product Portfolio Table 108. GSK Recent Development Table 109. Bayer Company Information Table 110. Bayer Business Overview Table 111. Bayer AT1 Receptor Antagonists Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 112. Bayer AT1 Receptor Antagonists Product Portfolio Table 113. Bayer Recent Development Table 114. Bristol-Myers Squibb Company Information Table 115. Bristol-Myers Squibb Business Overview Table 116. Bristol-Myers Squibb AT1 Receptor Antagonists Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 117. Bristol-Myers Squibb AT1 Receptor Antagonists Product Portfolio Table 118. Bristol-Myers Squibb Recent Development Table 119. Astra Zeneca Company Information Table 120. Astra Zeneca Business Overview Table 121. Astra Zeneca AT1 Receptor Antagonists Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 122. Astra Zeneca AT1 Receptor Antagonists Product Portfolio Table 123. Astra Zeneca Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. AT1 Receptor Antagonists Distributors List Table 127. AT1 Receptor Antagonists Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. AT1 Receptor Antagonists Product Image Figure 2. Global AT1 Receptor Antagonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AT1 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global AT1 Receptor Antagonists Sales (2021-2032) & (k tons) Figure 5. Global AT1 Receptor Antagonists Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global AT1 Receptor Antagonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Valsartan Image Figure 10. Telmisartan Image Figure 11. Losartan Image Figure 12. Irbesartan Image Figure 13. Olmesartan Image Figure 14. Azilsartan Image Figure 15. Global AT1 Receptor Antagonists Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 16. Global AT1 Receptor Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global AT1 Receptor Antagonists Sales Volume Share by Type (2021-2032) Figure 18. Global AT1 Receptor Antagonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global AT1 Receptor Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global AT1 Receptor Antagonists Sales Value Share by Type (2021-2032) Figure 21. Cardiovascular Diseases Image Figure 22. Kidney Diseases Image Figure 23. Hypertension Image Figure 24. Other Image Figure 25. Global AT1 Receptor Antagonists Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 26. Global AT1 Receptor Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global AT1 Receptor Antagonists Sales Volume Share by Application (2021-2032) Figure 28. Global AT1 Receptor Antagonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global AT1 Receptor Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global AT1 Receptor Antagonists Sales Value Share by Application (2021-2032) Figure 31. Global AT1 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 32. Global AT1 Receptor Antagonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global AT1 Receptor Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global AT1 Receptor Antagonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America AT1 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 36. North America AT1 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe AT1 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 38. Europe AT1 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific AT1 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific AT1 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America AT1 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 42. South America AT1 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa AT1 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa AT1 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. AT1 Receptor Antagonists Value Chain Figure 130. Manufacturing Cost Structure Figure 131. AT1 Receptor Antagonists Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Valsartan
  • Telmisartan
  • Losartan
  • Irbesartan
  • Olmesartan
  • Azilsartan
Applications
  • Cardiovascular Diseases
  • Kidney Diseases
  • Hypertension
  • Other
Companies covered
  • Teva Pharmaceutical
  • Sanofi
  • Jhonson and Johnson
  • Novartis
  • Merck
  • Eli Lilly
  • Pfizer
  • GSK
  • Bayer
  • Bristol-Myers Squibb
  • Astra Zeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global AT1 Receptor Antagonists Sales Value (2021-2032)
  4. 1.2.2 Global AT1 Receptor Antagonists Sales Volume (2021-2032)
  5. 1.2.3 Global AT1 Receptor Antagonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 AT1 Receptor Antagonists Market Dynamics
  1. 2.1 AT1 Receptor Antagonists Industry Trends
  2. 2.2 AT1 Receptor Antagonists Industry Drivers
  3. 2.3 AT1 Receptor Antagonists Industry Opportunities and Challenges
  4. 2.4 AT1 Receptor Antagonists Industry Restraints
3 AT1 Receptor Antagonists Market by Company
  1. 3.1 Global AT1 Receptor Antagonists Company Revenue Ranking in 2025
  2. 3.2 Global AT1 Receptor Antagonists Revenue by Company (2021-2026)
  3. 3.3 Global AT1 Receptor Antagonists Sales Volume by Company (2021-2026)
  4. 3.4 Global AT1 Receptor Antagonists Average Price by Company (2021-2026)
  5. 3.5 Global AT1 Receptor Antagonists Company Ranking (2024-2026)
  6. 3.6 Global AT1 Receptor Antagonists Company Manufacturing Base and Headquarters
  7. 3.7 Global AT1 Receptor Antagonists Company Product Type and Application
  8. 3.8 Global AT1 Receptor Antagonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global AT1 Receptor Antagonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 AT1 Receptor Antagonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 AT1 Receptor Antagonists Market by Type
  1. 4.1 AT1 Receptor Antagonists Type Introduction
  2. 4.1.1 Valsartan
  3. 4.1.2 Telmisartan
  4. 4.1.3 Losartan
  5. 4.1.4 Irbesartan
  6. 4.1.5 Olmesartan
  7. 4.1.6 Azilsartan
  8. 4.2 Global AT1 Receptor Antagonists Sales Volume by Type
  9. 4.2.1 Global AT1 Receptor Antagonists Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global AT1 Receptor Antagonists Sales Volume by Type (2021-2032)
  11. 4.2.3 Global AT1 Receptor Antagonists Sales Volume Share by Type (2021-2032)
  12. 4.3 Global AT1 Receptor Antagonists Sales Value by Type
  13. 4.3.1 Global AT1 Receptor Antagonists Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global AT1 Receptor Antagonists Sales Value by Type (2021-2032)
  15. 4.3.3 Global AT1 Receptor Antagonists Sales Value Share by Type (2021-2032)
5 AT1 Receptor Antagonists Market by Application
  1. 5.1 AT1 Receptor Antagonists Application Introduction
  2. 5.1.1 Cardiovascular Diseases
  3. 5.1.2 Kidney Diseases
  4. 5.1.3 Hypertension
  5. 5.1.4 Other
  6. 5.2 Global AT1 Receptor Antagonists Sales Volume by Application
  7. 5.2.1 Global AT1 Receptor Antagonists Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global AT1 Receptor Antagonists Sales Volume by Application (2021-2032)
  9. 5.2.3 Global AT1 Receptor Antagonists Sales Volume Share by Application (2021-2032)
  10. 5.3 Global AT1 Receptor Antagonists Sales Value by Application
  11. 5.3.1 Global AT1 Receptor Antagonists Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global AT1 Receptor Antagonists Sales Value by Application (2021-2032)
  13. 5.3.3 Global AT1 Receptor Antagonists Sales Value Share by Application (2021-2032)
6 AT1 Receptor Antagonists Regional Sales and Value Analysis
  1. 6.1 Global AT1 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global AT1 Receptor Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global AT1 Receptor Antagonists Sales by Region: 2021-2026
  4. 6.2.2 Global AT1 Receptor Antagonists Sales by Region (2027-2032)
  5. 6.3 Global AT1 Receptor Antagonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global AT1 Receptor Antagonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global AT1 Receptor Antagonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global AT1 Receptor Antagonists Sales Value by Region (2027-2032)
  9. 6.5 Global AT1 Receptor Antagonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America AT1 Receptor Antagonists Sales Value (2021-2032)
  12. 6.6.2 North America AT1 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe AT1 Receptor Antagonists Sales Value (2021-2032)
  15. 6.7.2 Europe AT1 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific AT1 Receptor Antagonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific AT1 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America AT1 Receptor Antagonists Sales Value (2021-2032)
  21. 6.9.2 South America AT1 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa AT1 Receptor Antagonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa AT1 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
7 AT1 Receptor Antagonists Country-level Sales and Value Analysis
  1. 7.1 Global AT1 Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global AT1 Receptor Antagonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global AT1 Receptor Antagonists Sales by Country (2021-2032)
  4. 7.3.1 Global AT1 Receptor Antagonists Sales by Country (2021-2026)
  5. 7.3.2 Global AT1 Receptor Antagonists Sales by Country (2027-2032)
  6. 7.4 Global AT1 Receptor Antagonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global AT1 Receptor Antagonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global AT1 Receptor Antagonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt AT1 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt AT1 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt AT1 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical AT1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical AT1 Receptor Antagonists Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi AT1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi AT1 Receptor Antagonists Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Jhonson and Johnson
  14. 8.3.1 Jhonson and Johnson Company Information
  15. 8.3.2 Jhonson and Johnson Business Overview
  16. 8.3.3 Jhonson and Johnson AT1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Jhonson and Johnson AT1 Receptor Antagonists Product Portfolio
  18. 8.3.5 Jhonson and Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis AT1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AT1 Receptor Antagonists Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck AT1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck AT1 Receptor Antagonists Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly AT1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly AT1 Receptor Antagonists Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer AT1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer AT1 Receptor Antagonists Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 GSK
  44. 8.8.1 GSK Company Information
  45. 8.8.2 GSK Business Overview
  46. 8.8.3 GSK AT1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GSK AT1 Receptor Antagonists Product Portfolio
  48. 8.8.5 GSK Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer AT1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bayer AT1 Receptor Antagonists Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb AT1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb AT1 Receptor Antagonists Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
  61. 8.11 Astra Zeneca
  62. 8.11.1 Astra Zeneca Company Information
  63. 8.11.2 Astra Zeneca Business Overview
  64. 8.11.3 Astra Zeneca AT1 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Astra Zeneca AT1 Receptor Antagonists Product Portfolio
  66. 8.11.5 Astra Zeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 AT1 Receptor Antagonists Value Chain Analysis
  2. 9.1.1 AT1 Receptor Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 AT1 Receptor Antagonists Sales Mode & Process
  6. 9.2 AT1 Receptor Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 AT1 Receptor Antagonists Distributors
  9. 9.2.3 AT1 Receptor Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst